Markus von Deimling, Laura S Mertens, Marc Furrer, Roger Li, Guus A H Tendijck, Jacob Taylor, Felice Crocetto, Moritz Maas, Andrea Mari, Renate Pichler, Marco Moschini, Karl H Tully, David D'Andrea, Ekaterina Laukhtina, Francesco Del Giudice, Gautier Marcq, Maud Velev, Andrea Gallioli, Simone Albisinni, Keiichiro Mori, Abhinav Khanna, Michael Rink, Margit Fisch, Andrea Minervini, Peter C Black, Yair Lotan, Philippe E Spiess, Bernhard Kiss, Shahrokh F Shariat, Benjamin Pradere
OBJECTIVE: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. PATIENTS AND METHODS: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa...
March 12, 2024: BJU International